TMPRSS2:erg fusion gene and androgen ablation therapy in prostate cancer

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 7, 2010, Pages 964-965

  Baldi, Elisabetta ^a   Bonaccorsi, Lorella ^a   Nesi, Gabriella ^a   Serni, Sergio ^a   Forti, Gianni ^a   Luzzatto, Lucio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b University of Florence ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

GENE EXPRESSION; GENETICS; HUMAN; LETTER; MALE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; GENE EXPRESSION; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS;

EID: 77954333516     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer:: an update. Arch Pathol Lab Med. 2009;133(7):1033-1040.
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497-511.
3. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgendependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66(22):10658-10663.
4. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009;69(15):6027-6032.
5. Bonaccorsi L, Nesi G, Nuti F, et al. Persistence of expression of the TMPRSS2:ERG fusion gene after presurgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer:: preliminary results. J Endocrinol Invest. 2009;32(7):590-596.
6. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69(4):1400-1406.
7. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2 (exon 0) -ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res. 2009;15(20):6398-6403.